CA2930681C - Fusion protein of collagen-binding domain and parathyroid hormone - Google Patents

Fusion protein of collagen-binding domain and parathyroid hormone Download PDF

Info

Publication number
CA2930681C
CA2930681C CA2930681A CA2930681A CA2930681C CA 2930681 C CA2930681 C CA 2930681C CA 2930681 A CA2930681 A CA 2930681A CA 2930681 A CA2930681 A CA 2930681A CA 2930681 C CA2930681 C CA 2930681C
Authority
CA
Canada
Prior art keywords
pth
collagen
seq
bone
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2930681A
Other languages
English (en)
French (fr)
Other versions
CA2930681A1 (en
Inventor
Osamu Matsushita
Robert C. Gensure
Joshua Sakon
Tulasi Ponnapakkam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagawa University NUC
Ochsner Clinic Foundation
University of Arkansas at Little Rock
Original Assignee
Kagawa University NUC
Ochsner Clinic Foundation
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagawa University NUC, Ochsner Clinic Foundation, University of Arkansas at Little Rock filed Critical Kagawa University NUC
Publication of CA2930681A1 publication Critical patent/CA2930681A1/en
Application granted granted Critical
Publication of CA2930681C publication Critical patent/CA2930681C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
CA2930681A 2007-04-09 2008-04-09 Fusion protein of collagen-binding domain and parathyroid hormone Active CA2930681C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92243307P 2007-04-09 2007-04-09
US60/922,433 2007-04-09
CA2683862A CA2683862C (en) 2007-04-09 2008-04-09 Fusion protein of collagen-binding domain and parathyroid hormone

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2683862A Division CA2683862C (en) 2007-04-09 2008-04-09 Fusion protein of collagen-binding domain and parathyroid hormone

Publications (2)

Publication Number Publication Date
CA2930681A1 CA2930681A1 (en) 2008-10-16
CA2930681C true CA2930681C (en) 2019-10-15

Family

ID=39831527

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2930681A Active CA2930681C (en) 2007-04-09 2008-04-09 Fusion protein of collagen-binding domain and parathyroid hormone
CA2683862A Active CA2683862C (en) 2007-04-09 2008-04-09 Fusion protein of collagen-binding domain and parathyroid hormone

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2683862A Active CA2683862C (en) 2007-04-09 2008-04-09 Fusion protein of collagen-binding domain and parathyroid hormone

Country Status (7)

Country Link
US (6) US8450273B2 (Direct)
EP (2) EP3091075B1 (Direct)
JP (4) JP5520811B2 (Direct)
CA (2) CA2930681C (Direct)
DK (2) DK2155874T3 (Direct)
ES (2) ES2675174T3 (Direct)
WO (1) WO2008124166A2 (Direct)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5520811B2 (ja) * 2007-04-09 2014-06-11 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合領域と副甲状腺ホルモンとの融合タンパク
CA2744286C (en) * 2008-11-19 2018-07-31 Tohoku University Fusion collagenase in which affinity tag is linked and method for producing the same
EP2405008A1 (en) * 2010-07-06 2012-01-11 LanthioPep B.V. Bacterial surface display of thioether-bridge-containing peptides
WO2012112767A2 (en) * 2011-02-16 2012-08-23 Purdue Research Foundation Collagen-targeted nanoparticles
EP2708246B1 (en) * 2011-05-13 2017-11-01 School Juridical Person Kitasato Institute Growth factor anchoring type bone graft material, method for producing growth factor anchoring type bone graft material, kit for producing growth factor anchoring type bone graft material.
DK3391899T3 (da) 2011-12-14 2020-08-24 Univ Arkansas Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
US8969290B2 (en) 2012-06-26 2015-03-03 Worcester Polytechnic Institute Matrix scaffold with antimicrobial activity
WO2016085280A1 (ko) 2014-11-28 2016-06-02 서울대학교산학협력단 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
US11213613B2 (en) 2015-06-12 2022-01-04 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Three-dimensional tissue scaffold with stem cell attracting element and use thereof
KR20250044469A (ko) 2016-03-01 2025-03-31 아센디스 파마 본 디지즈 에이/에스 Pth 프로드럭
LT3518961T (lt) 2016-09-29 2023-05-10 Ascendis Pharma Bone Diseases A/S Pth junginiai, pasižymintys mažu didžiausios ir mažiausios koncentracijos santykiu
NZ751969A (en) 2016-09-29 2023-04-28 Ascendis Pharma Bone Diseases As Dosage regimen for a controlled-release pth compound
CN109789221B (zh) 2016-09-29 2022-11-01 阿森迪斯药物骨疾病股份有限公司 控释pth的药物组合物
CN110114065A (zh) * 2016-11-30 2019-08-09 珀杜研究基金会 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生
JP7397440B2 (ja) 2017-02-10 2023-12-13 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合薬剤組成物およびその使用方法
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
CN107213517B (zh) * 2017-05-17 2020-03-27 宁波大学 一种复合骨水泥及其制备方法
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
KR101964376B1 (ko) * 2017-09-29 2019-04-01 주식회사 나이벡 부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
KR20250171437A (ko) 2019-02-11 2025-12-08 아센디스 파마 본 디지즈 에이/에스 Pth 접합체의 액체 약학 제제
WO2021030196A1 (en) * 2019-08-09 2021-02-18 Phasebio Pharmaceuticals, Inc. Elp fusion proteins comprising parathyroid hormone for controlled and sustained release
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
AU2023353057A1 (en) 2022-09-30 2025-05-01 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
WO1994022468A1 (en) 1993-04-02 1994-10-13 Anticancer, Inc. Method for delivering beneficial compositions to hair follicles
US5925552A (en) 1996-04-25 1999-07-20 Medtronic, Inc. Method for attachment of biomolecules to medical devices surfaces
US6147186A (en) 1996-07-31 2000-11-14 The General Hospital Corporation Parathyroid hormone-related peptide analogs
US6428579B1 (en) 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6387663B1 (en) * 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US20020102709A1 (en) * 1999-02-19 2002-08-01 Tetsuya Ishikawa Collagen-binding physiologically active polypeptide
AU2575000A (en) 1999-02-19 2000-09-04 Terumo Kabushiki Kaisha Collagen-binding physiologically active polypeptide
JP2001190280A (ja) * 1999-02-19 2001-07-17 Terumo Corp コラーゲン結合性生理活性ポリペプチド
US6908994B1 (en) * 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
WO2002014505A1 (en) * 2000-08-15 2002-02-21 Terumo Kabushiki Kaisha Collagen-binding hybrid polypeptide
JP2002058485A (ja) 2000-08-16 2002-02-26 Terumo Corp コラーゲン結合性を有する骨形成促進融合蛋白質
US20020063621A1 (en) 2000-09-01 2002-05-30 Next Planet, Inc. Method and apparatus for device communications
US6812217B2 (en) 2000-12-04 2004-11-02 Medtronic, Inc. Medical device and methods of use
DE60225185T2 (de) 2001-12-18 2009-02-19 Eidgenossisch Technische Hochschule Zürich Wachstumsfaktor-modifizierte proteinmatrizes zur geweberekonstruktion (tissue engineering)
US7429383B2 (en) * 2002-07-25 2008-09-30 The General Hospital Corporation Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
AU2003203316B2 (en) 2003-02-13 2007-01-11 Synthes Gmbh Injectable bone-replacement mixture
US20040220094A1 (en) 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
WO2005041865A2 (en) 2003-10-21 2005-05-12 Igf Oncology, Llc Compounds and method for treating cancer
US20050119183A1 (en) * 2003-11-12 2005-06-02 Nps Allelix Corp. Method for treating bone loss using parathyroid hormone
EP1557176A1 (en) 2004-01-26 2005-07-27 Ferring B.V. Treatment of bone metastases by means of PTH receptor agonists
CA2575416A1 (en) 2004-02-27 2005-09-09 The University Of Western Ontario Bone sialoprotein collagen-binding peptides
ATE505551T1 (de) * 2004-04-21 2011-04-15 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
CA2582552A1 (en) 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8802396B2 (en) 2005-12-26 2014-08-12 Yantai Zhenghai Bio-Technology Co., Ltd. Activated collagen scaffold materials and their special fused active restoration factors
JP5520811B2 (ja) 2007-04-09 2014-06-11 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合領域と副甲状腺ホルモンとの融合タンパク
JP2010172247A (ja) 2009-01-29 2010-08-12 Kitasato Institute 積層型高密度培養人工組織の製造方法及び積層型高密度培養人工組織
JPWO2011142425A1 (ja) 2010-05-12 2013-07-22 国立大学法人 香川大学 上皮層含有組織の再生材および再生評価方法
EP2708246B1 (en) 2011-05-13 2017-11-01 School Juridical Person Kitasato Institute Growth factor anchoring type bone graft material, method for producing growth factor anchoring type bone graft material, kit for producing growth factor anchoring type bone graft material.
DK3391899T3 (da) 2011-12-14 2020-08-24 Univ Arkansas Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein

Also Published As

Publication number Publication date
ES2583002T3 (es) 2016-09-16
JP5520811B2 (ja) 2014-06-11
US9528099B2 (en) 2016-12-27
US20150284701A1 (en) 2015-10-08
EP2155874A2 (en) 2010-02-24
JP2014040431A (ja) 2014-03-06
CA2683862A1 (en) 2008-10-16
CA2683862C (en) 2016-08-02
JP2016094385A (ja) 2016-05-26
EP3091075A1 (en) 2016-11-09
US20100129341A1 (en) 2010-05-27
EP2155874A4 (en) 2010-09-01
US10519213B2 (en) 2019-12-31
DK3091075T3 (en) 2018-07-16
WO2008124166A8 (en) 2009-11-05
JP6366653B2 (ja) 2018-08-01
US20190338010A1 (en) 2019-11-07
EP2155874B1 (en) 2016-05-11
JP5821066B2 (ja) 2015-11-24
WO2008124166A3 (en) 2009-01-15
EP3091075B1 (en) 2018-06-13
WO2008124166A2 (en) 2008-10-16
US9062300B2 (en) 2015-06-23
US10358471B2 (en) 2019-07-23
ES2675174T3 (es) 2018-07-09
US20130337017A1 (en) 2013-12-19
JP2010523671A (ja) 2010-07-15
US10202434B2 (en) 2019-02-12
JP2017025069A (ja) 2017-02-02
JP5989876B2 (ja) 2016-09-07
DK2155874T3 (en) 2016-08-01
US8450273B2 (en) 2013-05-28
US20190135890A1 (en) 2019-05-09
US20170101457A1 (en) 2017-04-13
CA2930681A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
US10519213B2 (en) Fusion proteins of collagen-binding domain and parathyroid hormone
JP6916918B2 (ja) 骨形成を促進するための組成物および方法
JP2000516579A (ja) 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト
US9248164B2 (en) Growth factor anchoring type bone graft material, method for producing growth factor anchoring type bone graft material, kit for producing growth factor anchoring type bone graft material, and method for forming bone
JP2004536056A (ja) Ｒａｎｋアンタゴニストの療法使用
JP2021535083A (ja) Ｃｄ８０細胞外ドメインｆｃ融合タンパク質投与レジメン
US11529391B2 (en) Reversing deficient hedgehog signaling restores deficient skeletal regeneration
WO2003082302A2 (en) Bioadhesive directed somatic cell therapy
WO2021158780A1 (en) Self-assembling prodrugs as immune boosters for cancer immunotherapy
Ponnapakkam Fusion proteins of collagen-binding domain and parathyroid hormone
AU2002257303A1 (en) Therapeutic use of rank antagonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161107